20/55
1.8 / 5 stars
All 55 Win/Lose results and 65 gray no-data contests shown below
ABEO Roast Me summary
ABEONA THERAPEUTICS INC. (ABEO). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth No data.
Trailing 1 year (4 quarters): 1 wins, 4 losses, 7 no dataLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinABEO / S&P 37.95% / 15.20% |
No dataABEO / S&P / 15.00% |
LoseABEO / S&P -255.71% / 50.40% |
| 2026-Q10/1 |
LoseABEO / S&P -14.99% / -4.33% |
No dataABEO / S&P / 11.30% |
No dataABEO / S&P / 27.70% |
| 2025-Q40/1 |
LoseABEO / S&P -0.19% / 2.65% |
No dataABEO / S&P / 9.00% |
No dataABEO / S&P / 13.40% |
| 2025-Q30/1 |
LoseABEO / S&P -7.04% / 8.12% |
No dataABEO / S&P / 4.61% |
No dataABEO / S&P / 13.45% |
| 2025-Q21/1 |
WinABEO / S&P 19.33% / 10.94% |
No dataABEO / S&P / 4.83% |
No dataABEO / S&P / 10.63% |
| 2025-Q10/1 |
LoseABEO / S&P -14.54% / -4.27% |
No dataABEO / S&P / 4.98% |
No dataABEO / S&P / 10.57% |
| 2024-Q40/1 |
LoseABEO / S&P -11.87% / 2.41% |
No dataABEO / S&P / 5.25% |
No dataABEO / S&P / 6.15% |
| 2024-Q31/1 |
WinABEO / S&P 49.06% / 5.89% |
No dataABEO / S&P / 5.89% |
No dataABEO / S&P / 6.11% |
| 2024-Q20/1 |
LoseABEO / S&P -41.52% / 4.28% |
No dataABEO / S&P / 5.38% |
No dataABEO / S&P / 5.12% |
| 2024-Q11/2 |
WinABEO / S&P 44.71% / 10.56% |
No dataABEO / S&P / 5.71% |
LoseABEO / S&P -1041.18% / 5.59% |
| 2023-Q42/2 |
WinABEO / S&P 19.00% / 11.69% |
WinABEO / S&P 147.52% / 6.81% |
No dataABEO / S&P / 7.78% |
| 2023-Q31/1 |
WinABEO / S&P 4.47% / -3.27% |
No dataABEO / S&P / 7.52% |
No dataABEO / S&P / -5.03% |
| 2023-Q21/1 |
WinABEO / S&P 42.91% / 8.74% |
No dataABEO / S&P / 9.50% |
No dataABEO / S&P / -8.57% |
| 2023-Q10/1 |
LoseABEO / S&P -8.44% / 7.50% |
No dataABEO / S&P / 10.77% |
No dataABEO / S&P / -15.69% |
| 2022-Q40/2 |
LoseABEO / S&P 1.32% / 7.56% |
LoseABEO / S&P -52.87% / 11.88% |
No dataABEO / S&P / -17.99% |
| 2022-Q30/1 |
LoseABEO / S&P -42.10% / -4.88% |
No dataABEO / S&P / 13.47% |
No dataABEO / S&P / -1.41% |
| 2022-Q20/1 |
LoseABEO / S&P -34.38% / -16.10% |
No dataABEO / S&P / 13.71% |
No dataABEO / S&P / 11.04% |
| 2022-Q10/1 |
LoseABEO / S&P -5.88% / -4.60% |
No dataABEO / S&P / 15.97% |
No dataABEO / S&P / 42.23% |
| 2021-Q40/2 |
LoseABEO / S&P -69.64% / 11.03% |
LoseABEO / S&P -70.00% / 15.00% |
No dataABEO / S&P / 96.40% |
| 2021-Q30/1 |
LoseABEO / S&P -28.21% / 0.58% |
No dataABEO / S&P / 10.77% |
No dataABEO / S&P / 69.42% |
| 2021-Q20/1 |
LoseABEO / S&P -17.02% / 8.55% |
No dataABEO / S&P / 6.58% |
No dataABEO / S&P / 51.81% |
| 2021-Q11/1 |
WinABEO / S&P 19.75% / 6.17% |
No dataABEO / S&P / -1.06% |
No dataABEO / S&P / 7.39% |
| 2020-Q41/1 |
WinABEO / S&P 53.92% / 12.15% |
No dataABEO / S&P / -3.72% |
No dataABEO / S&P / -33.42% |
| 2020-Q30/1 |
LoseABEO / S&P -65.07% / 8.93% |
No dataABEO / S&P / -2.04% |
No dataABEO / S&P / -27.10% |
| 2020-Q21/1 |
WinABEO / S&P 39.05% / 20.54% |
No dataABEO / S&P / -0.46% |
No dataABEO / S&P / -27.11% |
| 2020-Q10/1 |
LoseABEO / S&P -35.78% / -19.60% |
No dataABEO / S&P / 3.47% |
No dataABEO / S&P / -14.75% |
| 2019-Q41/1 |
WinABEO / S&P 44.69% / 9.07% |
No dataABEO / S&P / 5.36% |
No dataABEO / S&P / 2.99% |
| 2019-Q30/1 |
LoseABEO / S&P -52.72% / 1.70% |
No dataABEO / S&P / 5.02% |
No dataABEO / S&P / 0.21% |
| 2019-Q20/1 |
LoseABEO / S&P -35.05% / 4.30% |
No dataABEO / S&P / 6.64% |
No dataABEO / S&P / 8.65% |
| 2019-Q10/1 |
LoseABEO / S&P 3.08% / 13.65% |
No dataABEO / S&P / 8.12% |
No dataABEO / S&P / 14.29% |
| 2018-Q41/2 |
LoseABEO / S&P -44.22% / -13.52% |
WinABEO / S&P 258.18% / 9.05% |
No dataABEO / S&P / 18.23% |
| 2018-Q31/2 |
LoseABEO / S&P -20.00% / 7.71% |
WinABEO / S&P 508.31% / 10.21% |
No dataABEO / S&P / 19.06% |
| 2018-Q22/2 |
WinABEO / S&P 11.50% / 3.43% |
WinABEO / S&P 356.82% / 9.03% |
No dataABEO / S&P / 14.46% |
| 2018-Q11/2 |
LoseABEO / S&P -9.46% / -0.76% |
WinABEO / S&P 286.79% / 7.68% |
No dataABEO / S&P / 12.46% |
| 2017-Q40/2 |
LoseABEO / S&P -7.04% / 6.64% |
LoseABEO / S&P -5.85% / 7.03% |
No dataABEO / S&P / 13.82% |
| 2017-Q31/2 |
WinABEO / S&P 166.41% / 4.48% |
LoseABEO / S&P 3.54% / 5.68% |
No dataABEO / S&P / 17.57% |
| 2017-Q21/2 |
WinABEO / S&P 28.00% / 3.09% |
LoseABEO / S&P -11.17% / 4.83% |
No dataABEO / S&P / 17.74% |
| 2017-Q10/2 |
LoseABEO / S&P 3.09% / 6.07% |
LoseABEO / S&P -17.40% / 3.67% |
No dataABEO / S&P / 13.32% |
| 2016-Q40/2 |
LoseABEO / S&P -19.17% / 3.82% |
LoseABEO / S&P -14.52% / 2.09% |
No dataABEO / S&P / 7.05% |
| 2016-Q31/2 |
WinABEO / S&P 154.24% / 3.85% |
LoseABEO / S&P -19.92% / 0.20% |
No dataABEO / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ABEO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -13.32% | 20.78% |
| Annualized return | -13.32% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ABEO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -81.64% | 83.14% |
| Annualized return | -28.75% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ABEO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.48% | 319.30% |
| Annualized return | -25.15% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |